Evotec SE (EVTA.F)
Evotec SE
Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5,061
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Mario Polywka DPHIL, Ph.D. | CEO & Chairman of the Management Board & Member of the Supervisory Board | 60k | N/D | 1963 |
| Ms. Laetitia Rouxel | CFO & Member of Management Board | 890k | N/D | 1975 |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board | 582k | N/D | 1964 |
| Dr. Matthias Evers Ph.D. | Chief Business Officer & Member of Management Board | 130k | N/D | 1973 |
| Dr. Craig Johnstone Ph.D. | COO & Member of Management Board | 712k | N/D | 1970 |
| Ms. Anja Bosler | Principal Accounting Officer and Senior Vice President of Group Accounting | N/D | N/D | N/D |
| Mr. Volker Braun | Executive VP and Head of Global Investor Relations & ESG | N/D | N/D | N/D |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance | N/D | N/D | N/D |
| Gabriele Hansen | Senior VP & Head of Global Corporate Communications & Marketing | N/D | N/D | N/D |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations | 116k | N/D | 1950 |
Descripción
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Gestión corporativa
La calificación ISS Governance QuickScore de Evotec SE a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 4; Junta: 4; Derechos del accionista: 1; Compensación: 7.
